

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) Intraluminal device, suitable for implantation in a body, which device is provided with a coating, characterised in that the coating comprises:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen;

entactin; and

nidogen.

2. (original) Intraluminal device according to claim 1, characterised in that the coating comprises:

75-95% heparan sulfate;

3-10% laminin;

0.5-10% type IV collagen.

3. (canceled)

4. (previously presented) Intraluminal device according to claim 1, characterised in that the coating furthermore comprises a growth factor.

5. (original) Intraluminal device according to claim 4, characterised in that the growth factor is chosen from the group consisting of bFGF, IGF, TGF- β and VEGF.

6. (currently amended) ~~Intraluminal device according to claim 1, characterised in that the coating comprises Intraluminal device, suitable for implantation in a body, the device being provided with a coating that comprises:~~

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen; and

an antibiotic.

7. (original) Intraluminal device according to claim 6, characterised in that the antibiotic comprises gentamycine.

8. (previously presented) Intraluminal device according to claim 1, characterised in that the coating comprises vitronectine.

9. (currently amended) Intraluminal device according to claim 1, characterised in that the coating comprises:

85-95% heparan sulfate;

5-6% laminin[[],];

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors;

0.001-1% antibiotic.

10. (previously presented) Intraluminal device according to claim 1, characterised in that the prosthesis comprises a stent or a graft.

11. (previously presented) Coating suitable for a intraluminal device according to claim 1.

12. (currrently amended) Method for preparing a intraluminal device ~~according to claim 1~~, comprising the steps of:

- providing [[a]] an intraluminal device for implantation in a body;

- preparing a composition, comprising, in about 50 mg/ml solvent:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen;

the solvent being a suitable buffer or water;

- dipping the intraluminal device in the composition;

and

- drying the dipped intraluminal device.

13. (original) Method according to claim 12, characterised in that the composition comprises entactin and nidogen.

14. (previously presented) Method according to claim 12, characterised in that the composition furthermore comprises a growth factor, chosen from the group consisting of bFGF, IGF, TGF- β and VEGF.

15. (previously presented) Method according to claim 12, characterised in that the composition comprises an antibiotic.

16. (previously presented) Method according to claim 12, characterised in that the composition comprises vitronectin.

17. (previously presented) Method according to claim 12, characterised in that the composition comprises:

85-95% heparan sulfate;

5-6% laminin;

3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors;

0.001-1% antibiotic.